Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 520,293
  • Shares Outstanding, K 149,081
  • Annual Sales, $ 163,910 K
  • Annual Income, $ -62,260 K
  • EBIT $ -34 M
  • EBITDA $ -19 M
  • 60-Month Beta 2.65
  • Price/Sales 3.10
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 112.63% ( -12.03%)
  • Historical Volatility 54.30%
  • IV Percentile 78%
  • IV Rank 52.94%
  • IV High 198.96% on 02/05/24
  • IV Low 15.49% on 05/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 276
  • Volume Avg (30-Day) 297
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 13,226
  • Open Int (30-Day) 12,406

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.08
  • Number of Estimates 5
  • High Estimate -0.04
  • Low Estimate -0.11
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.02 +15.56%
on 11/22/24
3.87 -9.82%
on 12/06/24
+0.43 (+14.05%)
since 11/20/24
3-Month
2.69 +29.74%
on 10/01/24
3.87 -9.82%
on 12/06/24
+0.56 (+19.11%)
since 09/20/24
52-Week
1.69 +106.51%
on 04/26/24
3.87 -9.82%
on 12/06/24
+1.48 (+73.63%)
since 12/20/23

Most Recent Stories

More News
Xeris Biopharma: Q3 Earnings Snapshot

Xeris Biopharma: Q3 Earnings Snapshot

XERS : 3.49 (+2.35%)
Xeris Biopharma: Q2 Earnings Snapshot

Xeris Biopharma: Q2 Earnings Snapshot

XERS : 3.49 (+2.35%)
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 3.49 (+2.35%)
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSolâ„¢ Formulations

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 3.49 (+2.35%)
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJectâ„¢

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 3.49 (+2.35%)
Xeris Biopharma Appoints Ricki Fairley to Board of Directors

Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 3.49 (+2.35%)
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 3.49 (+2.35%)
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 3.49 (+2.35%)
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023

Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 3.49 (+2.35%)
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 3.49 (+2.35%)

Business Summary

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and...

See More

Key Turning Points

3rd Resistance Point 3.81
2nd Resistance Point 3.69
1st Resistance Point 3.59
Last Price 3.49
1st Support Level 3.37
2nd Support Level 3.25
3rd Support Level 3.15

See More

52-Week High 3.87
Last Price 3.49
Fibonacci 61.8% 3.04
Fibonacci 50% 2.78
Fibonacci 38.2% 2.52
52-Week Low 1.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar